A phase I study of FT819, a first-of-kind, off-the-shelf, iPSC-derived TCR less CD19 CAR T cell therapy for the treatment of relapsed/refractory b-cell malignancies Meeting Abstract
| Authors: | Park, J. H.; Jain, N.; Chen, A.; McGuirk, J. P.; Diaz, M.; Valamehr, B.; Chu, Y. W.; Castro, J. E. |
| Abstract Title: | A phase I study of FT819, a first-of-kind, off-the-shelf, iPSC-derived TCR less CD19 CAR T cell therapy for the treatment of relapsed/refractory b-cell malignancies |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-05 |
| Language: | English |
| ACCESSION: | WOS:000607547203167 |
| DOI: | 10.1182/blood-2020-142423 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 15 -- Source: Wos |
